Revance Therapeutics, Inc. (RVNC)
| Market Cap | 2.62B |
| Revenue (ttm) | 132.57M |
| Net Income (ttm) | -356.42M |
| Shares Out | 82.80M |
| EPS (ttm) | -4.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 972,415 |
| Open | 31.24 |
| Previous Close | 31.45 |
| Day's Range | 30.20 - 32.09 |
| 52-Week Range | 11.27 - 36.61 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 37.06 (+16.91%) |
| Earnings Date | May 9, 2023 |
About RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral can... [Read more]
Financial Performance
In 2022, RVNC's revenue was $132.57 million, an increase of 70.40% compared to the previous year's $77.80 million. Losses were -$356.42 million, 26.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is $37.06, which is an increase of 16.91% from the latest price.
News
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn't have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.
Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
Q4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively.
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, a...
Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q4 Earnings Expected to Decline
Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Revance Therapeutics, Inc. (RVNC) a Strong Momentum Stock: Buy Now?
Does Revance Therapeutics, Inc. (RVNC) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Pharma Stocks That Will Mint Millionaires
In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB) climbed 6% so far this year.
Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?
Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the...
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year ...
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License...
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will...
Revance to Participate in the Stifel 2022 Healthcare Conference
NASHVILLE, Tenn.
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Received FDA approval for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
NASHVILLE, Tenn.
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Should You Buy?
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
NASHVILLE, Tenn.
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
NASHVILLE, Tenn.
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ for Injection at the 2022 ASDS Annual Meeting
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ For Injection in the Aesthetic Surgery Journal
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ Injection for the Treatment of Upper Limb Spasticity at MDS
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock